EXHIBIT 99.1
CUBIST REPORTS FOURTH QUARTER AND FULL YEAR 2013 FINANCIAL RESULTS;
PROVIDES 2014 REVENUE GUIDANCE
· Full Year Total Net Revenues of $1.1 Billion, Up 14% Over 2012
· Full Year Non-GAAP Adjusted Operating Income of $189.7 Million; Full Year GAAP Operating Income of $26.4 Million
· Full Year Non-GAAP Diluted EPS of $1.45; Full Year GAAP Diluted EPS of $(0.27)
Lexington, Mass., January 23, 2014 — Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) today announced results for the fourth quarter and year ended December 31, 2013 and provided 2014 revenue guidance. The Company will host a conference call and webcast today at 5:00 p.m. ET to discuss the results and other business updates (details below).
Financial highlights for the fourth quarter of 2013 (unaudited):
· Total net revenues were $299.7 million compared to $245.9 million in the same period in 2012.
· Non-GAAP adjusted operating income was $43.6 million compared to $54.2 million in the fourth quarter of 2012. GAAP operating loss was $15.5 million compared to GAAP operating income of $45.3 million in the fourth quarter of 2012.
· Non-GAAP diluted earnings per share (EPS) was $0.29 compared to $0.42 in the fourth quarter of 2012. GAAP diluted loss per share was $(0.08) compared to GAAP diluted EPS of $0.51 in the fourth quarter of 2012.
Financial highlights for the full year of 2013 (unaudited):
· Total net revenues grew 14% to $1.1 billion compared to $926.4 million in 2012.
· Non-GAAP adjusted operating income was $189.7 million compared to $274.5 million in 2012. GAAP operating income was $26.4 million compared to $237.1 million in 2012.
· Non-GAAP diluted EPS was $1.45 compared to $2.15 in 2012. GAAP diluted loss per share was $(0.27) compared to GAAP diluted EPS of $2.10 in 2012.
“With our acquisitions of Trius and Optimer and positive ceftolozane/tazobactam data, we solidified our global antibiotics leadership in 2013 and enhanced our position in the acute care space,” said Michael Bonney, CEO of Cubist. “With strong growth in our marketed products, a robust pipeline, and significant momentum coming out of last year, we enter 2014 focused on executing our major, near-term milestones and driving further progress on our Building Blocks of Growth.”
As previously announced on January 13, 2014, fourth quarter 2013 U.S. CUBICIN® (daptomycin for injection) net product revenues were $248.9 million, up 15% over the fourth quarter of 2012, and full year U.S. CUBICIN net product revenues were $908.0 million, up 12% over 2012. Cubist’s share of full year 2013 international CUBICIN revenues was $58.7 million, which represents a 16% increase over $50.5 million in 2012. U.S. net product revenues of DIFICID® (fidaxomicin) following the completion of the Company’s acquisition of Optimer
65 Hayden Avenue, Lexington, MA 02421 P 781.860.8660 F 781.861.0566 www.cubist.com
Pharmaceuticals, Inc. (Optimer) on October 24, 2013 were $12.2 million. Cumulative net sales of DIFICID in the U.S. and Canada from October 1, 2013, through December 31, 2013, were $15.8 million, which includes $3.5 million in net sales recorded by Optimer prior to the acquisition. Fourth quarter ENTEREG® (alvimopan) net product revenues were $13.8 million, up 26% compared to $10.9 million in the fourth quarter of 2012. Full year ENTEREG net product revenues were $51.0 million, up 27% compared to $40.2 million in 2012.
In the fourth quarter, total net revenues were $299.7 million, up 22% over $245.9 million in the same period in 2012. Full year total net revenues grew 14% to $1.1 billion compared to $926.4 million in 2012.
Reflecting the critical investments the Company made in its late-stage development programs, including ceftolozane/tazobactam, and the initial build-out of its European infrastructure, non-GAAP adjusted operating income was $43.6 million compared to $54.2 million in the fourth quarter of 2012; GAAP operating loss in the fourth quarter was $15.5 million compared to operating income of $45.3 million in 2012. Non-GAAP adjusted operating income for the full year was $189.7 million compared to $274.5 million in 2012; GAAP operating income for the full year 2013 was $26.4 million compared to $237.1 million in 2012.
As of December 31, 2013, Cubist had $578.6 million in cash, cash equivalents and investments. The total number of Cubist’s common shares outstanding as of December 31, 2013 was 74,428,087.
2014 Revenue Guidance
The company also announced the following 2014 annual revenue guidance (in millions):
TOTAL NET REVENUE | | $1,190 - $1,275 |
U.S. Net CUBICIN | | $970 - $1,020 |
All Other Product Revenue | | $205 - $235 |
Service and Other Revenues | | $15 - $20 |
Recent Highlights & Milestones
Acquisition of Optimer Pharmaceuticals
· On October 24, 2013, Cubist completed the acquisition of Optimer Pharmaceuticals, Inc. for an aggregate upfront cash consideration of $551 million, excluding transaction costs.
Tedizolid phosphate — a novel oxazolidinone being developed for both intravenous (I.V.) and oral administration for the treatment of certain serious Gram-positive bacterial infections, including those caused by methicillin-resistant Staphylococcus aureus (MRSA); acquired by Cubist as part of its September 11, 2013 acquisition of Trius Therapeutics, Inc.
· On December 30, 2013, Cubist announced that the U.S. Food and Drug Administration (FDA) accepted the Company’s New Drug Application (NDA) for tedizolid phosphate with Priority Review. The FDA has assigned a Prescription Drug User Fee Act (PDUFA) action date of June 20, 2014.
· Phase 3 pivotal studies in Hospital-Acquired Bacterial Pneumonia (HABP)/Ventilator-Associated Bacterial Pneumonia (VABP) are expected to begin in the first quarter of 2014.
· In the first half of 2014, the Company plans to submit a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA).
Ceftolozane/tazobactam — a potential first-line therapy being studied for the treatment of certain serious Gram-negative bacterial infections, including those caused by multi-drug resistant Pseudomonas aeruginosa.
· On November 25, 2013 and December 16, 2013, respectively, Cubist announced positive top-line results from the Company’s pivotal Phase 3 clinical trials of ceftolozane/tazobactam in complicated urinary tract infections (cUTI) and complicated intra-abdominal infections (cIAI).
· Cubist is on track to file an NDA for ceftolozane/tazobactam in cUTI and cIAI in the first half of 2014.
· The Company expects to initiate a pivotal Phase 3 trial to assess the safety and efficacy of ceftolozane/tazobactam in HABP/VABP in the first half of 2014.
· Cubist plans to submit an MAA for ceftolozane/tazobactam in cUTI and cIAI to the EMA in the second half of 2014.
CB-618 — a novel, broad-spectrum beta-lactamase inhibitor (BLI) investigational compound discovered by Cubist to combat resistance to certain beta-lactam antibiotics and serious infections, including those caused by carbapenem-resistant Enterobacteriaceae (CREs) and Klebsiella pneumoniae carbapenemases (KPCs).
· On January 10, 2014, Cubist submitted a Clinical Trial Application (CTA) to the Dutch Competent Authority and Ethics Committee to initiate a first-in-human study of CB-618 in the Netherlands. The Company has since received approval from the Dutch Competent Authority and Ethics Committee to initiate the study.
********************CONFERENCE CALL & WEBCAST INFORMATION***********************
Cubist will host a conference call and live audio webcast to discuss both its fourth quarter and
full year 2013 financial results, business activities and financial outlook.
WHEN: Thursday, January 23, 2014 at 5:00 p.m. ET
U.S./CANADA ATTENDEE DIAL-IN: (855) 319-7654
INTERNATIONAL ATTENDEE DIAL-IN: (484) 756-4327
Attendee Passcode: 29092793
24-HOUR REPLAY U.S./CANADA: (855) 859-2056
24-HOUR REPLAY INTERNATIONAL: (404) 537-3406
Conference ID: 29092793
CALL WILL ALSO BE BROADCAST LIVE, LISTEN ONLY, VIA THE WEB AT:
https://cubist.webex.com/cubist/onstage/g.php?t=a&d=625478620
Attendee Password: 01232014
Replay will be available for 30 days via the Internet at www.cubist.com
*********************************************************************************
Use of Non-GAAP Financial Measures
Cubist has presented certain non-GAAP financial measures, including non-GAAP adjusted operating income, non-GAAP net income, non-GAAP diluted earnings per share, non-GAAP cost of product revenues, non-GAAP R&D expenses, non-GAAP SG&A expenses, non-GAAP other income (expense) and non-GAAP provision for income taxes. These non-GAAP financial measures exclude certain amounts, expenses or income, from the corresponding financial measures determined in accordance with U.S. Generally Accepted Accounting Principles (GAAP). Management believes this non-GAAP information is useful for investors, taken in conjunction with Cubist’s GAAP financial statements, because it provides greater transparency regarding Cubist’s operating performance. Management uses these measures, among other factors, to assess and analyze operational results and trends and to make financial and operational decisions. Non-GAAP information is not prepared under a comprehensive set of accounting rules and should only be used to supplement an understanding of Cubist’s operating results as reported under GAAP, not as a substitute for GAAP. In addition, these non-GAAP financial measures are unlikely to be comparable with non-GAAP information provided by other companies. The determination of the amounts that are excluded from non-GAAP financial measures is a matter of management judgment and depends upon, among other factors, the nature of the underlying expense or income amounts. Reconciliations between these non-GAAP financial measures and the most comparable GAAP financial measures for the fourth quarters and years ended December 31, 2013 and 2012 are included in the tables accompanying this press release after the unaudited condensed consolidated financial statements.
About Cubist
Cubist Pharmaceuticals, Inc. is a biopharmaceutical company focused on the research, development, and commercialization of pharmaceutical products that address significant unmet medical needs in the acute care environment. Cubist is headquartered in Lexington, Mass. Additional information can be found at Cubist’s web site at www.cubist.com. Connect with Cubist on Twitter @cubistbiopharma and @cubistcareers, LinkedIn, or YouTube.
Forward-Looking Statements
This press release contains forward-looking statements. Any statements contained herein which do not describe historical facts, including but not limited to, statements regarding: our unaudited expected fourth quarter and full year 2013 financial results; our 2014 revenue guidance; the therapeutic and commercial potential of our products and product candidates; the expected timing for commencing clinical trials, including our planned Phase 3 pivotal studies for HABP and VABP for tedizolid phosphate and ceftolozane/tazobactam, and for regulatory filings and responses for our products and product candidates, including our planned tedizolid phosphate and ceftolozane/tazobactam MAA submissions to the EMA and our NDA for ceftolozane/tazobactam in cUTI and cIAI; our Phase 3 clinical data for ceftolozane/tazobactam in cUTI and cIAI; and our Building Blocks of Growth five-year goals through 2017 are forward-looking statements which involve risks and uncertainties that could cause actual results to differ materially from those discussed in such forward-looking statements. Such risks and uncertainties include, among others: the risk that our final fourth quarter and full year 2013 and 2014 audited financial results will differ materially from our expected results disclosed in this release; risks related to drug development and commercialization, including the fact that drug discovery and development is complex, time consuming, expensive and fraught with a high risk of failure; our ability to achieve our short-term and our long-term goals, including as a result of our ability to continue to grow revenues from the sale of CUBICIN, DIFICID and ENTEREG, generic and other competition, manufacturing issues, our ability to successfully develop, gain marketing approval for and commercially launch our product candidates for their planned indications and on their expected timelines, and our ability to discover, in-license or acquire new products and product candidates; regulatory developments in the United States and foreign countries, including the risk that the FDA and foreign regulatory authorities may not agree with our interpretation of the results from our clinical studies of ceftolozane/tazobactam and tedizolid, may not approve on a timely basis or at all, our marketing authorization applications for ceftolozane/tazobactam and tedizolid phosphate or may require additional data, analysis, information or further studies that may not be clinically feasible or financially practicable; the review of our NDA for tedizolid may take longer than anticipated due to internal FDA constraints; any marketing approval for any of our product candidates may impose significant limitations on its use and additional post-marketing requirements; competitive risks from current and future therapeutic alternatives to our products and product candidates, including generic competitors such as Teva, Hospira and Strides; our ability to maintain and enforce intellectual property protection for our products and product candidates; additional clinical trials of our products and product candidates may produce negative or inconclusive results or may not be initiated or conducted in a timely manner; technical difficulties or excessive costs relating to the manufacture or supply of our products and product candidates, including our ability to work with, and the performance of our third party contract manufacturers that manufacture and supply our products and product candidates on our behalf; our ability to work with, and the performance of our third party contract research organizations that help us conduct our clinical trials; and those additional factors discussed in our most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission. We caution investors not to place considerable reliance on the forward-looking statements contained in this press release. These forward-looking statements speak only as of the date of this document, and we undertake no obligation to update or revise any of these statements.
Contacts | |
INVESTORS: | MEDIA: |
Eileen C. McIntyre, (781) 860-8533 | Julie DiCarlo, (781) 860-8063 |
Vice President, Investor Relations | Senior Director, Corporate Communications |
eileen.mcintyre@cubist.com | julie.dicarlo@cubist.com |
Tables Follow
CUBIST PHARMACEUTICALS, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
UNAUDITED
(in thousands)
| �� | December 31, | |
| | 2013 | | 2012 | |
ASSETS | |
Cash, cash equivalents and investments | | $ | 578,558 | | $ | 979,396 | |
Accounts receivable, net | | 123,155 | | 93,467 | |
Inventory | | 116,829 | | 79,440 | |
Property and equipment, net | | 177,544 | | 166,465 | |
Deferred tax assets, net | | 52,108 | | 14,190 | |
In-process research and development | | 896,400 | | 272,700 | |
Goodwill | | 383,018 | | 114,130 | |
Other intangible assets, net | | 721,066 | | 152,830 | |
Other assets | | 97,143 | | 59,767 | |
| | | | | |
Total assets | | $ | 3,145,821 | | $ | 1,932,385 | |
| | | | | |
LIABILITIES AND STOCKHOLDERS’ EQUITY | |
Accounts payable and accrued expenses | | $ | 276,955 | | $ | 209,236 | |
Deferred tax liabilities, net | | 357,802 | | 103,081 | |
Deferred revenue | | 37,421 | | 40,875 | |
Contingent consideration | | 223,322 | | 189,213 | |
Debt and other liabilities, net | | 856,590 | | 399,232 | |
Total liabilities | | 1,752,090 | | 941,637 | |
| | | | | |
Total stockholders’ equity | | 1,393,731 | | 990,748 | |
| | | | | |
Total liabilities and stockholders’ equity | | $ | 3,145,821 | | $ | 1,932,385 | |
CUBIST PHARMACEUTICALS, INC.
CONDENSED CONSOLIDATED STATEMENTS OF INCOME
UNAUDITED
(in thousands, expect share and per share data)
| | Three Months Ended
December 31, | | Twelve Months Ended
December 31, | |
| | 2013 | | 2012 | | 2013 | | 2012 | |
Revenues: | | | | | | | | | |
U.S. CUBICIN product revenues, net | | $ | 248,896 | | $ | 216,041 | | $ | 907,978 | | $ | 809,200 | |
U.S. ENTEREG product revenues, net | | 13,759 | | 10,941 | | 51,024 | | 40,171 | |
U.S. DIFICID product revenues, net | | 12,194 | | — | | 12,194 | | — | |
Total U.S. product revenues, net | | 274,849 | | 226,982 | | 971,196 | | 849,371 | |
International product revenues | | 20,888 | | 14,478 | | 61,237 | | 50,454 | |
Service revenues | | 1,243 | | 3,705 | | 12,287 | | 23,249 | |
Other revenues | | 2,761 | | 754 | | 9,722 | | 3,285 | |
Total revenues, net | | 299,741 | | 245,919 | | 1,054,442 | | 926,359 | |
| | | | | | | | | |
Costs and expenses: | | | | | | | | | |
Cost of product revenues | | 80,605 | | 61,474 | | 260,310 | | 230,057 | |
Research and development | | 124,918 | | 89,154 | | 477,740 | | 277,729 | |
Impairment charges | | 55,300 | | 38,700 | | 55,300 | | 38,700 | |
Contingent consideration | | (54,857 | ) | (36,017 | ) | (47,577 | ) | (29,021 | ) |
Selling, general and administrative | | 85,995 | | 47,333 | | 257,940 | | 171,788 | |
Restructuring charges | | 23,290 | | — | | 24,319 | | — | |
Total costs and expenses | | 315,251 | | 200,644 | | 1,028,032 | | 689,253 | |
| | | | | | | | | |
Operating (loss) income | | (15,510 | ) | 45,275 | | 26,410 | | 237,106 | |
| | | | | | | | | |
Other income (expense), net | | (14,003 | ) | (7,553 | ) | (70,054 | ) | (37,510 | ) |
| | | | | | | | | |
(Loss) income before income taxes | | (29,513 | ) | 37,722 | | (43,644 | ) | 199,596 | |
| | | | | | | | | |
(Benefit) provision for income taxes | | (23,507 | ) | (115 | ) | (25,073 | ) | 45,521 | |
| | | | | | | | | |
Net (loss) income | | $ | (6,006 | ) | $ | 37,837 | | $ | (18,571 | ) | $ | 154,075 | |
| | | | | | | | | |
Basic (loss) income per share | | $ | (0.08 | ) | $ | 0.59 | | $ | (0.27 | ) | $ | 2.42 | |
Diluted (loss) income per share | | $ | (0.08 | ) | $ | 0.51 | (1) | $ | (0.27 | ) | $ | 2.10 | (1) |
| | | | | | | | | |
Shares used in calculating: | | | | | | | | | |
Basic (loss) income per share | | 74,209,165 | | 64,504,616 | | 68,160,798 | | 63,766,209 | |
Diluted (loss) income per share | | 74,209,165 | | 82,030,774 | | 68,160,798 | | 81,444,658 | |
(1) Includes add back of interest expense, debt issuance costs and debt discount amortization on 2017 Notes to income, net of tax effect
CUBIST PHARMACEUTICALS, INC.
RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL INFORMATION
UNAUDITED
(in thousands)
| | Three Months Ended
December 31, | | Twelve Months Ended
December 31, | |
| | 2013 | | 2012 | | 2013 | | 2012 | |
| | | | | | | | | |
Operating (loss) income reconciliation: | | | | | | | | | |
GAAP operating (loss) income | | $ | (15,510 | ) | $ | 45,275 | | $ | 26,410 | | $ | 237,106 | |
Cost of product revenues adjustments(1) | | 13,723 | | 6,270 | | 30,342 | | 22,364 | |
Research and development adjustments(1) | | 4,975 | | — | | 57,280 | | 1,996 | |
Impairment charges | | 55,300 | | 38,700 | | 55,300 | | 38,700 | |
Contingent consideration | | (54,857 | ) | (36,017 | ) | (47,577 | ) | (29,021 | ) |
Restructuring charges | | 23,290 | | — | | 24,319 | | — | |
Selling, general and administrative adjustments(1) | | 16,726 | | — | | 43,601 | | 3,397 | |
Non-GAAP adjusted operating income | | $ | 43,647 | | $ | 54,228 | | $ | 189,675 | | $ | 274,542 | |
Non-GAAP other income (expense) (2) | | (5,711 | ) | (3,015 | ) | (15,143 | ) | (12,551 | ) |
Non-GAAP provision for income taxes(2) | | (13,704 | ) | (18,551 | ) | (58,375 | ) | (91,917 | ) |
Non-GAAP net income | | $ | 24,232 | | $ | 32,662 | | $ | 116,157 | | $ | 170,074 | |
(1) Detail on the adjustments included herein is provided in the tables below.
(2) A reconciliation to the most comparable GAAP financial measure is included in the tables below.
CUBIST PHARMACEUTICALS, INC.
RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL INFORMATION
UNAUDITED
(in thousands, except percentages)
| | Three Months Ended
December 31, | | Twelve Months Ended
December 31, | |
| | 2013 | | 2012 | | 2013 | | 2012 | |
Cost of product revenues adjustments: | | | | | | | | | |
GAAP cost of product revenues | | $ | 80,605 | | $ | 61,474 | | $ | 260,310 | | $ | 230,057 | |
Intangible asset amortization | | (12,110 | ) | (4,565 | ) | (25,639 | ) | (18,331 | ) |
Inventory fair value step-up | | (1,613 | ) | (1,705 | ) | (4,703 | ) | (4,033 | ) |
Non-GAAP cost of product revenues | | $ | 66,882 | | $ | 55,204 | | $ | 229,968 | | $ | 207,693 | |
| | | | | | | | | |
Product gross margin reconciliation: | | | | | | | | | |
GAAP product gross margin | | 72.7 | % | 74.5 | % | 74.8 | % | 74.4 | % |
Intangible asset amortization | | 4.1 | % | 1.9 | % | 2.5 | % | 2.0 | % |
Inventory fair value step-up | | 0.5 | % | 0.7 | % | 0.5 | % | 0.4 | % |
Non-GAAP product gross margin | | 77.3 | % | 77.1 | % | 77.8 | % | 76.8 | % |
| | | | | | | | | |
Research and development expenses adjustments: | | | | | | | | | |
GAAP research and development expenses | | $ | 124,918 | | $ | 89,154 | | $ | 477,740 | | $ | 277,729 | |
Acquisition-related expenses | | (4,369 | ) | — | | (16,674 | ) | (1,996 | ) |
Intangible asset amortization | | (606 | ) | — | | (606 | ) | — | |
Upfront license fees | | — | | — | | (40,000 | ) | — | |
Non-GAAP research and development expenses | | $ | 119,943 | | $ | 89,154 | | $ | 420,460 | | $ | 275,733 | |
| | | | | | | | | |
Selling, general and administrative expenses adjustments: | | | | | | | | | |
GAAP selling, general and administrative expenses | | $ | 85,995 | | $ | 47,333 | | $ | 257,940 | | $ | 171,788 | |
Acquisition-related expenses | | (16,726 | ) | — | | (43,601 | ) | (3,397 | ) |
Non-GAAP selling, general and administrative expenses | | $ | 69,269 | | $ | 47,333 | | $ | 214,339 | | $ | 168,391 | |
| | | | | | | | | |
Other income (expense) reconciliation: | | | | | | | | | |
GAAP other income (expense) | | $ | (14,003 | ) | $ | (7,553 | ) | $ | (70,054 | ) | $ | (37,510 | ) |
Debt discount amortization | | 8,292 | | 3,800 | | 20,333 | | 17,244 | |
Loss on extinguishment of convertible notes | | — | | 738 | | 34,578 | | 4,467 | |
Loss on disposal of property and equipment | | — | | — | | — | | 3,248 | |
Non-GAAP other income (expense) | | $ | (5,711 | ) | $ | (3,015 | ) | $ | (15,143 | ) | $ | (12,551 | ) |
| | | | | | | | | |
Benefit (provision) for income taxes: | | | | | | | | | |
GAAP benefit (provision) for income taxes | | $ | 23,507 | | $ | 115 | | $ | 25,073 | | $ | (45,521 | ) |
Tax adjustment | | (37,211 | ) | (18,666 | ) | (83,448 | ) | (46,396 | ) |
Non-GAAP provision for income taxes | | $ | (13,704 | ) | $ | (18,551 | ) | $ | (58,375 | ) | $ | (91,917 | ) |
CUBIST PHARMACEUTICALS, INC.
RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL INFORMATION
UNAUDITED
(in thousands, except share and per share amounts)
| | Three Months Ended
December 31, | | Twelve Months Ended
December 31, | |
| | 2013 | | 2012 | | 2013 | | 2012 | |
| | | | | | | | | |
Reconciliation of net (loss) income: | | | | | | | | | |
GAAP net (loss) income | | $ | (6,006 | ) | $ | 37,837 | | $ | (18,571 | ) | $ | 154,075 | |
Non-cash debt discount amortization | | 8,292 | | 3,800 | | 20,333 | | 17,244 | |
Loss on extinguishment of convertible notes | | — | | 738 | | 34,578 | | 4,467 | |
Loss on disposal of property and equipment | | — | | — | | — | | 3,248 | |
Intangible asset amortization | | 12,716 | | 4,565 | | 26,245 | | 18,331 | |
Inventory fair value step-up | | 1,613 | | 1,705 | | 4,703 | | 4,033 | |
Restructuring charges | | 23,290 | | — | | 24,319 | | — | |
Acquisition-related expenses | | 21,095 | | — | | 60,275 | | 5,393 | |
Upfront license fees | | — | | — | | 40,000 | | — | |
Impairment charges | | 55,300 | | 38,700 | | 55,300 | | 38,700 | |
Contingent consideration | | (54,857 | ) | (36,017 | ) | (47,577 | ) | (29,021 | ) |
Tax adjustment (1) | | (37,211 | ) | (18,666 | ) | (83,448 | ) | (46,396 | ) |
Non-GAAP net income | | $ | 24,232 | | $ | 32,662 | | $ | 116,157 | | $ | 170,074 | |
| | | | | | | | | |
Reconciliation of diluted earnings (loss) per share: | | | | | | | | | |
GAAP diluted (loss) earnings per share | | $ | (0.08 | ) | $ | 0.51 | | $ | (0.27 | ) | $ | 2.10 | |
Non-GAAP dilutive adjustments | | 0.37 | (2) | (0.09 | )(2) | 1.72 | (2) | 0.05 | (2) |
Non-GAAP diluted earnings per share | | $ | 0.29 | | $ | 0.42 | | $ | 1.45 | | $ | 2.15 | |
| | | | | | | | | |
Reconciliation of shares used in diluted per share calculation: | | | | | | | | | |
GAAP shares used in diluted earnings per share | | 74,209,165 | | 82,030,774 | | 68,160,798 | | 81,444,658 | |
Non-GAAP dilutive share adjustments | | 20,277,221 | (3) | 295,688 | (4) | 18,518,507 | (3) | 1,962,273 | (4) |
Non-GAAP shares used in diluted earnings per share | | 94,486,386 | | 82,326,462 | | 86,679,305 | | 83,406,931 | |
(1) The methodology used to compute the tax adjustments above was revised in Q1 2013 to reflect the tax effect of non-GAAP adjustments and to include material, non-recurring discrete items for the period. The prior year tax adjustments have been revised to conform to the current year’s presentation.
(2) Includes impact of non-GAAP adjustments from GAAP net income to non-GAAP net income and add back of interest expense and debt issuance costs on Cubist’s outstanding convertible notes, net of tax effect
(3) Additional dilutive weighted average shares issuable upon conversion of Cubist’s outstanding convertible notes and exercise or vesting of Cubist’s outstanding equity awards
(4) Additional dilutive weighted average shares issuable upon conversion of Cubist’s outstanding convertible notes
